Paradigm Biocapital Advisors LP Vaxcyte, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $3.1 Billion
- Q3 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 3,784,755 shares of PCVX stock, worth $184 Million. This represents 4.39% of its overall portfolio holdings.
Number of Shares
3,784,755
Previous 3,372,837
12.21%
Holding current value
$184 Million
Previous $110 Million
24.33%
% of portfolio
4.39%
Previous 5.12%
Shares
7 transactions
Others Institutions Holding PCVX
# of Institutions
316Shares Held
132MCall Options Held
493KPut Options Held
162K-
Janus Henderson Group PLC London, X013.1MShares$638 Million0.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.3MShares$600 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$583 Million7.4% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$484 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.32MShares$405 Million0.18% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.89B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...